Molecular Human Reproduction, Vol 4, 83-86, Copyright © 1998 by Oxford University Press
MS Rein, WL Powell, FC Walters, S Weremowicz, RM Cantor, RL Barbieri and CC Morton
Uterine leiomyomata (myomas) are associated with a variety of
characteristic cytogenetic abnormalities. The significance of these
chromosomal aberrations in the pathobiology of myomas remains to be
determined. The present study investigated the relationship between myoma
cytogenetic abnormalities and size. A total of 114 myoma specimens were
obtained from 92 patients undergoing myomectomy or hysterectomy. The
maximum diameter of each myoma was measured and a portion of each myoma
obtained for cytogenetic analysis. Karyotypes were analysed and categorized
as normal, abnormal (non-mosaic) or mosaic. Cytogenetic analyses revealed
73 (64%) normal, 20 (18%) abnormal (non-mosaic), and 21 (18%) mosaic
karyotypes. Mean myoma diameter was 6.5+/-0.44 cm with a range of 0.4-27
cm. Differences between the mean myoma diameter of specimens with normal
versus abnormal karyotypes was determined by the Kruskal-Wallis test. The
mean myoma diameter among specimens with abnormal (non-mosaic) karyotypes
was significantly greater than myomas with normal karyotypes (10.2+/- 5.9
versus 5.9+/-4.2 cm; P < 0.001). The proportion of abnormal (non-
mosaic) karyotypes in myomas >6.5 cm was compared to myomas <6.5 cm
by chi2-analysis; myomas >6.5 cm demonstrated a significantly higher
proportion of abnormal (non-mosaic) karyotypes when compared to myomas
<6.5 cm (75 versus 34%; P < 0.02). In summary, a significant
relationship exists between clonal cytogenetic abnormalities and myoma
size, suggesting that chromosomal abnormalities associated with individual
myomas enhance myoma growth.
JOURNAL ARTICLE
Cytogenetic abnormalities in uterine myomas are associated with myoma size
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Peng, J. Laser, G. Shi, K. Mittal, J. Melamed, P. Lee, and J.-J. Wei Antiproliferative Effects by Let-7 Repression of High-Mobility Group A2 in Uterine Leiomyoma Mol. Cancer Res., April 1, 2008; 6(4): 663 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Stewart and C. C. Morton The genetics of uterine leiomyomata: what clinicians need to know. Obstet. Gynecol., April 1, 2006; 107(4): 917 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shozu, K. Murakami, T. Segawa, T. Kasai, H. Ishikawa, K. Shinohara, M. Okada, and M. Inoue Decreased Expression of Early Growth Response-1 and Its Role in Uterine Leiomyoma Growth Cancer Res., July 1, 2004; 64(13): 4677 - 4684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Mason, R. A. Nowak, C. C. Morton, and J. J. Castellot Jr. Heparin Inhibits the Motility and Proliferation of Human Myometrial and Leiomyoma Smooth Muscle Cells Am. J. Pathol., June 1, 2003; 162(6): 1895 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hennig, U. Deichert, U. Bonk, B. Thode, S. Bartnitzke, and J. Bullerdiek Chromosomal translocations affecting 12q14-15 but not deletions of the long arm of chromosome 7 associated with a growth advantage of uterine smooth muscle cells Mol. Hum. Reprod., December 1, 1999; 5(12): 1150 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Morton Many Tumors and Many Genes : Genetics of Uterine Leiomyomata Am. J. Pathol., October 1, 1998; 153(4): 1015 - 1020. [Full Text] [PDF]
|
|